Slide 1: Lantern Pharma IPO Roadshow Presentation
Nasdaq: LTRN 1 Lantern Pharma IPO ROADSHOW Presentation Leveraging A.I., Machine Learning & Genomics to Rescue, Repurpose and Develop Targeted Cancer Therapies
Slide 2: Free Writing Prospectus
Nasdaq: LTRN 2 FREE WRITING PROSPECTUS • We have filed a registration statement (including a prospectus) with the SEC for the offering to which this communication rel ate s. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with
Slide 3: Special Note Regarding Forward-Looking Statements
Nasdaq: LTRN 3 SPECIAL NOTE REGARDING FORWARD - LOOKING STATEMENTS This presentation contains forward - looking statements that involve substantial risks and uncertainties. All statements, other th an statements of historical fact, contained in this presentation, including statements regarding our s
Slide 4: IPO Offering Summary
Nasdaq: LTRN 4 IPO Offering Summary ISSUER LANTERN PHARMA INC. Proposed Aggregate Offering $25,008,000 Price Range $15.00 to $17.00 Proposed Symbol LTRN – Nasdaq Shares Offered 1,563,000 Pre - IPO Common Shares Outstanding as converted 4,467,594 Post - IPO Common Shares Outstanding 6,030,594 Use of
Slide 5: Management Team
Nasdaq: LTRN 5 Highly experienced in the pharma, drug development and oncology industry Management Team Jeff Donald Keyser, Ph.D., J.D., MPA • Board Chairman • Founder of Renibus Therapeutics and ZSPharma Franklyn Prendergast, M.D., Ph.D. Emeritus • Board of Governors and Board of Trustees, Mayo Cli
Slide 6: Rescuing failed or abandoned drugs with A.I.
Nasdaq: LTRN 6 Drugs that have failed clinical trials or have been abandoned by pharma and biotech companies in late stage trials • Big data (genomic, clinical, response) assembled and analyzed • Patient subgroups identified through machine learning and artificial intelligence • Mechanisms of action
Slide 7: Oncology drug development is costly, risky, and inefficient
Nasdaq: LTRN 7 Current oncology drug development is costly, risky, and inefficient … a perfect problem area for artificial intelligence & machine learning 3.4% Avg. success rate of oncology drugs $1B+ Average developmental cost per oncology drug 17,000+ Oncology trials conducted from 2001 - 2015 2X
Slide 8: Critical need to rescue failed drugs and stratify patients
Nasdaq: LTRN 8 “... low efficacies of cancer drugs might be attributed to the heterogeneity of the tested patient population , which essentially dilutes the strong therapeutic effect that a drug might have on a specific patient subgroup .” Thiebault Geoux , Ph.D. Chemistry - Elsevier 11/9/2015 10.1
Slide 9: Mega Trends Shaping Drug Development
Nasdaq: LTRN 9 Solving unmet needs and creating opportunities in personalizing cancer therapy by capitalizing on emerging technologies and industry trends 1. Increased access to validated genomic & biomarker data 2. Availability of well tolerated and clinically active but failed or abandoned compoun
Slide 10: A.I.-driven drug discovery is a rapidly growing market
Nasdaq: LTRN 10 Drug discovery and development driven by A.I. is a rapidly growing market in response to fundamental shifts in the industry and a re - tooling of R&D 0 200 400 600 800 1000 1200 2016 2024 *Source: Biopharmatrend.com , PMLiVE, and Global Market Insights, Inc. ~$4B A.I. - driven Drug D
Slide 11: Scalable, Unique Artificial Intelligence Platform – RADR
Nasdaq: LTRN 11 Scalable, Unique Artificial Intelligence Platform – RADR® • 275+ Million datapoints covering over 140+ drug/tumor interactions • Active collaboration with NCI in oncology therapeutics • Guides development of patient stratification and CDx strategy • Validated in multiple case studies
Slide 12: RADR platform data for predicting drug response
Nasdaq: LTRN 12 Lantern’s powerful A.I. platform is being developed with a pure focus on predicting drug outcome and drug response using a depth of interrelated biomarker and clinical data , including: • Complete transcriptome data • RNA gene expression data • Drug sensitivity data • DNA copy number
Slide 13: Lantern's Unique & Rapidly Developing Pipeline
Nasdaq: LTRN 13 Lantern’s Unique & Rapidly Developing Pipeline Phase I Phase II LP - 184 LP - 100 (Irofulven) LP - 300 Drug Preclinical Indication Prostate Cancer Successfully partnered & out - licensed for up to $14M Non - Small Cell Lung Cancer (Never - Smokers) Solid Tumors (Location agnostic tum
Slide 14: Target market segments comprise nearly 1M patients annually
Nasdaq: LTRN 14 Target market segments comprise nearly 1M patients annually worldwide Prostate Cancer Non - Small Cell Lung Cancer (NSCLC) Ovarian, Pancreatic & Liver Cancer 1.3 million 2018 Estimated Global Incidence 208,000 2018 Estimated G lobal metastatic hormone - resistant prostate cancer subp
Slide 15: Overview of Lantern's Small Molecule Portfolio
Nasdaq: LTRN 15 Overview of Lantern’s Small Molecule Portfolio LP - 100, Irofulven LP - 184 LP - 300 • DNA Damaging Agent • Mediates cytotoxicity through multiple mechanisms such as DNA adduct formation, RNA polymerase stalling and redox protein modification • Actively enrolling in a precision medic
Slide 16: LP-100 (Irofulven): out-licensed to Oncology Venture
Nasdaq: LTRN 16 LP - 100 ( Irofulven ): out - licensed to Oncology Venture and in an active, genetically - guided clinical trial for prostate cancer History of Safety, Tolerability & Efficacy in Multiple Clinical Trials • Out - licensed to Oncology Venture (OV) in 2016 • Lantern Pharma can receive u
Slide 17: LP-100: Historical phase II trial results in prostate cancer
Nasdaq: LTRN 17 LP - 100 ( Irofulven ): Historical* phase II trial results in prostate cancer *Historical data from Hart et al., Randomized phase II trial of irofulven/prednisone, irofulven/capecitabine/prednisone, or mitoxantrone/prednisone in hormone refractory prostate cancer (HRPC) patients fail
Slide 18: LP-300 in development for female never-smokers with NSCLC
Nasdaq: LTRN 18 LP - 300 in development for female never - smokers with NSCLC adenocarcinoma based on strong historical data Mechanism of action • Disulfide bond disrupting agent • Disrupts by covalently modifying Cysteine • Inhibits and modulates activity of proteins in NSCLC pathways (ALK, EGFR, M
Slide 19: Lung Cancer in Never-Smokers – a hidden but rising disease
Nasdaq: LTRN 19 Lung Cancer in Never - Smokers (LCINS) – a hidden but rising disease • 7 th leading cause of death among patients with solid tumors • More frequent in women with ~2/3 of patients with no reported smoking history • Adenocarcinoma is the most common histology accounting for ~60% of non
Slide 20: LP-300 Phase III subgroup 2-year survival
Nasdaq: LTRN 20 Source: Phase 3 clinical trial, study ID DMS32212R, conducted by BioNumerik Pharmaceuticals - subpopulations receiving paclitaxel/cisplatin 30% 51% 63% 72% 25% 31% 28% 32% All patients Females never-Smokers Female never-Smokers 2 Year Survival % LP-300 + Cisplatin/ Paclitaxel Placebo
Slide 21: LP-300 survival curves by subgroup
Nasdaq: LTRN 21 All never - smokers N = 87, HR = 0.519 (p value 0.0462) Survival months Survival probability 0 10 20 30 1.0 0.8 0.6 0.4 0.2 0.0 LP - 300 + Cisplatin/Paclitaxel Placebo + Cisplatin/Paclitaxel All females N = 114, HR = 0.579 (p value 0.0477) LP - 300 + Cisplatin/Paclitaxel Placebo + Ci
Slide 22: Proposed Phase II trial design for LP-300
Nasdaq: LTRN 22 Proposed design for relaunching of Phase II clinical trial for LP - 300 in a targeted patient population Histology / demographic/ smoking history screening LP - 300 + standard of care (Dosing every 3 weeks and up to 8 treatment cycles) Efficacy Endpoints Never - smoker NSCLC Adenocar
Slide 23: LP-184 for solid tumors and PTGR1 expressing cancers
Nasdaq: LTRN 23 LP - 184 for solid tumors and certain PTGR1 expressing cancers Unique Features • Hydroxyurea Methylacylfulvene • Nanomolar potency across multiple solid tumor (pancreas, prostate, liver) and glioblastoma cell lines • Broad anti - tumor agent that counteracts multi - drug resistance a
Slide 24: LP-184 tumor regression in mouse model
Nasdaq: LTRN 24 LP - 184 treatment resulted in greater tumor regression in a mouse model with human cancer Source: Staake et al., Bioorganic & Medicinal Chemistry Letters (2016) 10 1 0.1 10 20 30 Time (days) Relative Tumor Weight No Drug LP - 100, 10 mg/kg LP - 184, 10 mg/kg LP - 184, 20 mg/kg Drugs
Slide 25: Proposed LP-184 mechanism of action
Nasdaq: LTRN 25 Proposed LP - 184 mechanism of action based on acylfulvene drugs 1. Potential synergistic drug combinations due to involvement w/ DNA repair pathway and supported by gene correlation studies 2. Approved drugs in certain drug classes have been identified to be synergistic with LP - 18
Slide 26: LP-184 in vitro potency over approved chemotherapeutics
Nasdaq: LTRN 26 1 10 100 1,000 10,000 100,000 1,000,000 SNU387_Liver H2228_NSCLC H1944_NSCLC OV90_Ovary NIHOVCAR3_Ovary IC50 [ nM ] Cell Line ID_Cancer Type LP-184 Cisplatin Pemetrexed Nanomolar potency Micromolar potency LP - 184 shows a 10x – 3,800x increase in in vitro potency over approved chemo
Slide 27: LP-184 in Glioblastoma
Nasdaq: LTRN 27 LP - 184 shows significant promise in improving patient outcomes in Glioblastoma (GBM) – a rare cancer with median survival of < 1 year 37.4 46.4 47.7 231 274000 513000 293000 129000 1 10 100 1,000 10,000 100,000 1,000,000 SF268 SF295 SNB75 U251 IC50 [ nM ] Comparative sensitivity of
Slide 28: RADR – A robust and scalable platform
Nasdaq: LTRN 28 RADR ® - A robust and scalable platform for accelerating the development of targeted cancer therapy, precision trials and Companion Dx Model Data Sets Data Sources AI Methods Being Deployed • >275+ million transcriptomic and drug sensitivity data points • >140 drug - tumor interactio
Slide 29: RADR identifies genetic markers and signatures
Nasdaq: LTRN 29 RADR ® identifies genetic markers and signatures for precision oncology drug development, clinical response prediction and CDx enablement Output & Signature Development Process Platform Architecture Success in Blinded Predictions Oncology Patient Records & Response Information Drug -
Slide 30: RADR Workflow Details
Nasdaq: LTRN 30 Uses machine learning methods to train on datasets Parameter tuning and model development and evaluation Biomarker Pa nel or Gene Signature for a CDx Guidance for clinical trial design & studies Training Set Optimal model used on testing dataset Genetic D ata Drug S ensitivity Data G
Slide 31: Our Intellectual Property Portfolio
Nasdaq: LTRN 31 108 Issued Patents Our Intellectual Property Portfolio – Extensive and continually growing position of over 108 issued and in - licensed patents and 7 patent applications across 14 patent families Methods of Use Composition of Matter Drug Sensitivity & Response Signatures using Bioma
Slide 32: Studies & Collaborations With Top Tier Academic & Research Partners
Nasdaq: LTRN 32 Studies & Collaborations With Top Tier Academic & Research Partners
Slide 33: Heavy investment & investor interest in A.I. driven drug development
Nasdaq: LTRN 33 Heavy investment & investor interest in A.I. driven drug development Company Investment Feb. 2020 IPO (NASDAQ: SDGR) $226+ M. total Latest 07/2019 private raise Mar. 2018 IPO (NASDAQ: BTAI) $50+ M. total Latest 03/2018 private raise Valuation* $3,600+ Million $232 M. raised at IPO $9
Slide 34: Value Building Milestones & Inflection Points
Nasdaq: LTRN 34 Value Building Milestones & Inflection Points x Readout from targeted Phase 2 trial in Europe in prostate cancer by Q4, 2020 / Q2, 2021 x Launch Ph.2 clinical trial for LP - 300 in NSCLC (never - smokers) x Launch Ph.1 clinical trial for LP - 184 in solid tumors x Launch Ph.1/2 clini
Slide 35: Use of Proceeds
Nasdaq: LTRN 35 Use of Proceeds GROSS PROCEEDS FROM IPO $25,008,000 Advance Clinical Programs for Lead Candidates - LP - 300 and LP - 184: Clinical Trial Testing, Preclinical Studies, Biomarker Studies & Manufacturing $13,500,000 AI Platform, RADR® Development and Expansion & Data Collaborations $2,
Slide 36: Pre IPO Capitalization Table
Nasdaq: LTRN 36 *Assuming a 1.74 for 1 stock split immediately prior to closing of the offering ** Conversion of Series A Preferred stock into 2,438,865 shares of common stock Pre IPO Capitalization Table LANTERN PHARMA INC.* Common Shares Outstanding ** 4,467,594 Warrants (WAEP $3.13) 262,003 Optio
Slide 37: Investment Highlights
Nasdaq: LTRN 37 Investment Highlights - Lantern Pharma has a unique, growing and validated foundation for the future of cancer therapy and patient care Focused on cancer drug market segments with clear clinical need , understood mechanisms, targeted patient populations that exceed 1 Million , and mu
Slide 38: Thank you!
Nasdaq: LTRN 38 Lantern Pharma IPO ROADSHOW Presentation Thank you!